Better Science, Better Health
“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.
“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.
“Better Science, Better Health” has three core areas of focus:
- Harnessing real world evidence for better decision-making and create better patient outcomes
- Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
- Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines
Latest Events
Webinar: COVID-19 VACCINES ARE COMING – A Magic Bullet or a Load of Blanks?
Wednesday, 30 September, 20.00 – 21.00 CET (2.00 pm – 3.00 pm, US Eastern)
Given the huge societal and economic impacts of the coronavirus in Europe, everyone is hopeful that COVID-19 vaccines will soon be available – but what happens next?
According to an Economist report from August 2018, in the past decade vaccination rates in some European countries have often fallen below those in parts of Africa. It claims that Italy, France and Serbia have lower child-vaccination rates than Burundi, Rwanda and Senegal.
After billions of Euros have been invested by governments, what will happen if many EU citizens are unwilling to take the vaccine? What can be done now to ensure that those who need the COVID-19 vaccine most are treated first when the vaccines are available?
Furthermore, how do EU member states plan on measuring and monitoring the safety of vaccines that have been rapidly put onto the market ̶ and who will ultimately be accountable? And from the patient’s perspective, how can we build trust around the EU’s management of COVID-19, which has become increasingly politicised?
EHDEN Online Roadshow
A series of 3 webinars focussed on
‘The Role of Health Data in the Post Covid-19 Era’
Goal of the webinar series:
The webinars will present an opportunity to explore utilisation of Real World Data/Real World Evidence in Spain and Spanish-speaking countries, as well as to compare and analyse wider European and Spanish RWD/RWE initiatives in the spirit of creating collaborations and strengthening relationships.
Who pays for hope? – treating cancer early
9 September, 2020, 8.30 CET
Cancer is still often considered a death sentence. It is the second leading cause of death globally and will soon overtake cardiovascular disease as the number one killer. As a result, the main effect that people expect treatments to have is to prolong overall survival either through curing the disease or by slowing its progression and reducing cancer-related symptoms. Indeed, great progress has been made in recent years and cancer mortality grows at a much slower pace than cancer incidence.
This webinar intends to discuss different perspectives on how funding decisions should be approached depending on the setting of the disease.
Latest News
EHFG: CAR-T: The evolution of a revolution?
Do CAR-T – Chimeric antigen receptor T-cell – therapies have the potential to revolutionise cancer care? These therapies are disrupting traditional concepts of immuno-oncology, manufacturing, delivery and value across Europe. However, for many, there remain a number of open questions that need to be addressed. This session highlighted the transformative potential of these therapies, and sceptical voices who will focus on the unknown variables and where current challenges lie.
Health care 2024: Privacy in the age of digital medicine
Duane Schulthess, managing Director of Vital Transformation, was invited as an expert by POLITICO to participate in “Health Care 2024,” a survey-driven series of online debates in which POLITICO will explore how the European Union can best tackle health policy. In this installment of Health Care 2024 POLITICO asks: Can the EU gain benefits from sharing health data without weakening privacy — and if so, how?
Podcast Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation
Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics.
Newsletter
Register now to receive all the latest news and events.
Latest Research
Our consultancy services
The Economic Pandemic: Aggressive Testing Is Vital to Controlling the Spread of COVID19 and Saving Europe’s Economy
8th April 2020
By Duane Schulthess, Gergana Koleva, Anja Schiel, Harry P. Bowen, and Luca Pani
For the last month, a debate has raged over which approach to managing the spread of COVID-19 is correct. One aspect of this debate is about the efficacy of widespread testing.
Videos
Visit our youtube channel to view all of our videos.